No survival difference after successful 131I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 2, 2010, Pages 276-283

  Verburg, Frederik Anton ^a,b   Stokkel, Marcel P M ^c   Düren, Christian ^a   Verkooijen, Robbert B T ^c   Mäder, Uwe ^a   Van Isselt, Johannes W ^b   Marlowe, Robert J ^d   Smit, Johannes W ^c   Reiners, Christoph ^a   Luster, Markus ^e  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Spencer Fontayne Corporation   (United States)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

131I Ablation; Differentiated thyroid cancer; Prognostic factors; Recurrence; Risk stratification; Survival

Indexed keywords

IODINE 131; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIFFERENTIATED THYROID CARCINOMA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG UPTAKE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LABORATORY DIAGNOSIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RADIOFREQUENCY ABLATION; RECURRENCE RISK; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GERMANY; HUMANS; INCIDENCE; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 77949271510     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1315-6     Document Type: Article

References (25)

1. DS Cooper GM Doherty BR Haugen RT Kloos SL Lee SJ Mandel, et al. 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer Thyroid 16 109 142 10.1089/thy.2006.16.109 16420177
2. F Pacini M Schlumberger H Dralle R Elisei JW Smit W Wiersinga 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium Eur J Endocrinol 154 787 803 10.1530/eje.1.02158 1:CAS:528:DC%2BD28XmsVKrurY%3D 16728537 (Pubitemid 43997716)
3. M Schlumberger G Berg O Cohen L Duntas F Jamar B Jarzab, et al. 2004 Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective Eur J Endocrinol 150 105 112 10.1530/eje.0.1500105 1:CAS:528:DC%2BD2cXitVWltLg%3D 14763906 (Pubitemid 38312801)
4. EL Mazzaferri RJ Robbins CA Spencer LE Braverman F Pacini L Wartofsky, et al. 2003 A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma J Clin Endocrinol Metab 88 1433 1441 10.1210/jc.2002-021702 1:CAS:528:DC%2BD3sXjtFCmu7k%3D 12679418 (Pubitemid 36623351)
5. Sobin LH, Wittekind C, editors. TNM classification of malignant tumours. 5th ed. Berlin: Springer; 1997.
6. Sobin LH, Wittekind C, editors. TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002.
7. FA Verburg R Verkooijen M Stokkel J van Isselt 2009 The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I Nuklearmedizin 48 138 142 1:STN:280: DC%2BD1MrjtVGltQ%3D%3D 19384451
8. RB Verkooijen FA Verburg JW van Isselt CJ Lips JW Smit MP Stokkel 2008 The success rate of I-131 ablation in differentiated thyroid cancer: comparison of uptake-related and fixed-dose strategies Eur J Endocrinol 159 301 307 10.1530/EJE-08-0062 1:CAS:528:DC%2BD1cXht1Chs77L 18567668
9. RB Verkooijen MP Stokkel JW Smit EK Pauwels 2004 Radioiodine-131 in differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation strategy Eur J Nucl Med Mol Imaging 31 499 506 10.1007/s00259-003-1405- 9 1:CAS:528:DC%2BD2cXitFygsL0%3D 14722676
10. FA Verburg B de Keizer CJ Lips PM Zelissen JM de Klerk 2005 Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients Eur J Endocrinol 152 33 37 10.1530/eje.1.01819 1:CAS:528:DC%2BD2MXptFaktA%3D%3D 15762184 (Pubitemid 40185450)
11. JM de Klerk B de Keizer PM Zelissen CM Lips HP Koppeschaar 2000 Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy Nucl Med Commun 21 529 532 10.1097/00006231-200006000-00005 10894561
12. CA Spencer LM Bergoglio M Kazarosyan S Fatemi JS LoPresti 2005 Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas J Clin Endocrinol Metab 90 5566 5575 10.1210/jc.2005-0671 1:CAS:528:DC%2BD2MXhtFWjt7zJ 15985472 (Pubitemid 41415459)
13. CA Spencer 2004 Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies J Clin Endocrinol Metab 89 3702 3704 10.1210/jc.2004-0986 1:CAS:528:DC%2BD2cXmslKmtrg%3D 15292292 (Pubitemid 39071459)
14. EL Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
15. RT Kloos EL Mazzaferri 2005 A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later J Clin Endocrinol Metab 90 5047 5057 10.1210/jc.2005-0492 1:CAS:528:DC%2BD2MXhtVWkur7E 15972576 (Pubitemid 41262253)
16. RM Tuttle M Brokhin G Omry AJ Martorella SM Larson RK Grewal, et al. 2008 Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal J Nucl Med 49 764 770 10.2967/jnumed.107.049072 18413378 (Pubitemid 351717542)
17. F Pacini M Capezzone R Elisei C Ceccarelli D Taddei A Pinchera 2002 Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum tg levels after initial treatment J Clin Endocrinol Metab 87 1499 1501 10.1210/jc.87.4.1499 1:CAS:528: DC%2BD38XivFKltr8%3D 11932271 (Pubitemid 34615228)
18. F Pacini E Molinaro MG Castagna L Agate R Elisei C Ceccarelli, et al. 2003 Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma J Clin Endocrinol Metab 88 3668 3673 10.1210/jc.2002-021925 1:CAS:528:DC%2BD3sXmsFOkt78%3D 12915653 (Pubitemid 37034512)
19. RJ Robbins JT Chon M Fleisher SM Larson RM Tuttle 2002 Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 87 3242 3247 10.1210/jc.87.7.3242 1:CAS:528:DC%2BD38XlsVGjtbo%3D 12107232 (Pubitemid 34816372)
20. FA Verburg U Mader M Luster C Reiners 2009 Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases Eur J Endocrinol 160 619 624 10.1530/EJE-08-0805 1:CAS:528:DC%2BD1MXpsFOktbk%3D 19158232
21. BR Haugen F Pacini C Reiners M Schlumberger PW Ladenson SI Sherman, et al. 1999 A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer J Clin Endocrinol Metab 84 3877 3885 10.1210/jc.84.11.3877 1:CAS:528:DyaK1MXntlOqt74%3D 10566623
22. F Pacini E Molinaro F Lippi MG Castagna L Agate C Ceccarelli, et al. 2001 Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma J Clin Endocrinol Metab 86 5686 5690 10.1210/jc.86.12.5686 1:CAS:528:DC%2BD3MXptVyltb4%3D 11739420 (Pubitemid 33152608)
23. FA Verburg M Dietlein M Lassmann M Luster C Reiners 2009 Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma Eur J Nucl Med Mol Imaging 36 343 346 10.1007/s00259-008-0997-5 19050874
24. ID Hay IR McDougall JC Sisson 2008 Perspective: the case against radioiodine remnant ablation in patients with well-differentiated thyroid carcinoma J Nucl Med 49 1395 1397 10.2967/jnumed.108.052654
25. RM Tuttle R Leboeuf AR Shaha 2008 Medical management of thyroid cancer: a risk adapted approach J Surg Oncol 97 712 716 10.1002/jso.21010 18493922 (Pubitemid 351812974)